How were Neos Therapeutics' earnings last quarter?

Neos Therapeutics, Inc. (NASDAQ:NEOS) issued its quarterly earnings results on Monday, November, 9th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.05. The company had revenue of $12.54 million for the quarter.

What is Mark Tengler's approval rating as Neos Therapeutics' CEO?

10 employees have rated Neos Therapeutics Chief Executive Officer Mark Tengler on Glassdoor.com . Mark Tengler has an approval rating of 26% among the company's employees. This puts Mark Tengler in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Neos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neos Therapeutics investors own include Verastem (VSTM) , SCYNEXIS (SCYX) , TherapeuticsMD (TXMD) , TG Therapeutics (TGTX) , AcelRx Pharmaceuticals (ACRX) , Exelixis (EXEL) , Rigel Pharmaceuticals (RIGL) , Progenics Pharmaceuticals (PGNX) , T2 Biosystems (TTOO) and Agile Therapeutics (AGRX) .

When did Neos Therapeutics IPO?

Neos Therapeutics (NEOS) raised $60 million in an IPO on Thursday, July 23rd 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

NASDAQ:NEOS

Neos Therapeutics (NEOS) Stock Price, News & Analysis

→ He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad)

Free NEOS Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $1.06
▼
$1.18
50-Day Range: $0.77
▼
$1.18
52-Week Range: $0.45
▼
$1.68

Volume: 15.01 million shs
Average Volume: 7.44 million shs
Market Capitalization: $57.22 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Neos Therapeutics alerts:

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Neos Therapeutics Stock (NASDAQ:NEOS)

Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

NEOS Stock News Headlines

March 3, 2024 | afr.com

Avenue Bank wins full APRA licence, bank guarantees in sight

February 9, 2024 | benzinga.com

Presidio Partners 2007 GP, L.P.'s Net Worth

April 17, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

December 14, 2023 | finance.yahoo.com

USAntibiotics Expands Leadership Team with Appointment of Steven Lutz to Vice President of Strategic Accounts

September 11, 2023 | finanznachrichten.de

Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors

July 10, 2023 | finanznachrichten.de

Aytu BioPharma, Inc.: Aytu BioPharma Announces Submission of Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement

July 10, 2023 | finance.yahoo.com

Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

May 29, 2023 | finance.yahoo.com

ADHD Therapeutics Market Size Worth USD 19740 Million by 2030 at 7.80% CAGR – Report by Market Research Future (MRFR)

April 17, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

May 12, 2023 | marketwatch.com

Overview of Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Dynamics and Trends for 2023-2030

April 28, 2023 | marketwatch.com

Global ADHD Medication Market Analysis and Business Growth Outlook [2023-2030]

April 11, 2023 | marketwatch.com

Attention Deficit Hyperactivity Disorder (ADHD) Market by Product Type and Consumers-2030

April 4, 2023 | marketwatch.com

Attention Deficit Hyperactivity Disorder (ADHD) Market 2023 Size and Forecast to 2031

April 3, 2023 | benzinga.com

Attention Deficit Hyperactivity Disorder Market to Register a Steady CAGR of 4.40% Between 2023 – 2031 | Growth Plus Reports

March 30, 2023 | marketwatch.com

ADHD Medication Market 2023 Size and Growth Forecast to 2028

March 27, 2023 | marketwatch.com

2023 Attention Deficit Hyperactivity Disorder (ADHD) Market: Top Players Best Practices and Sales Forecast 2030

March 24, 2023 | marketwatch.com

ADHD Medication Market Outlook and Forecast till 2030

March 21, 2023 | marketwatch.com

Attention Deficit Hyperactivity Disorder (ADHD) Market Insights and Forecast to 2028

March 16, 2023 | marketwatch.com

This report on ADHD Medication market presents a timeline of technical development and discusses how it affects the market.

March 14, 2023 | marketwatch.com

ADHD Medication Market Analysis, Share by 2028

February 27, 2023 | marketwatch.com

Global Methylphenidate Drug Market Research Covers, Future Trends and Opportunities, Past, Present Data, and Deep Analysis 2030 By VMReports

February 19, 2023 | marketwatch.com

Children Attention Deficit and Hyperactivity Disorder Market 2023: Strategies for Expanding into New Markets across Regions 2029

February 15, 2023 | marketwatch.com

Attention Deficit Hyperactivity Disorder (ADHD) Market Growth, Business Overview and Forecast to 2028

January 23, 2023 | afr.com

Avenue Bank aims to free up cash for small business

January 20, 2023 | finance.yahoo.com

Nykode Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 11, 2023 | marketwatch.com

Attention Deficit Hyperactivity Disorder (ADHD) Market Size 2028 Size Estimation, New Investment Opportunities with Top Countries Data

October 12, 2022 | marketwatch.com

Attention Deficit and Hyperactivity Disorder Market Analysis Research Report, Challenges, Scopes, Market Share, Revenue, and Forecasts 2022 to 2028

See More Headlines

Receive NEOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2020
Today: 4/17/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:NEOS
CUSIP: N/A
CIK: 1467652
Web: www.neostx.com
Phone: 972-408-1300
Fax: N/A
Employees: 213
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-16,900,000.00
Net Margins: -38.35%
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -28.46%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.66
Quick Ratio: 0.53

Sales & Book Value

Annual Sales: $64.65 million
Price / Sales: 0.89
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.12) per share
Price / Book: -9.58

Miscellaneous

Outstanding Shares: 49,757,000
Free Float: N/A
Market Cap: $57.22 million
Optionable: Optionable
Beta: 1.50

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Gerald W. McLaughlin (Age 53)
CEO, Pres & Director
Comp: $561.95k
Mr. Richard I. Eisenstadt (Age 63)
CFO, Treasurer & Corp. Sec.
Comp: $387.59k
Ms. Margaret Cabano
VP of Operations
Mr. John P. Limongelli (Age 51)
Sr. VP, Gen. Counsel & Corp. Sec.
Mr. Joe Calarco
Chief Compliance Officer
Ms. Sarah Foster
VP of HR
Mr. Russ McMahen
Sr. VP of R&D

Key Competitors

View All Competitors

NEOS Stock Analysis - Frequently Asked Questions

How were Neos Therapeutics' earnings last quarter?: Neos Therapeutics, Inc. (NASDAQ:NEOS) issued its quarterly earnings results on Monday, November, 9th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.05. The company had revenue of $12.54 million for the quarter.
What is Mark Tengler's approval rating as Neos Therapeutics' CEO?: 10 employees have rated Neos Therapeutics Chief Executive Officer Mark Tengler on Glassdoor.com. Mark Tengler has an approval rating of 26% among the company's employees. This puts Mark Tengler in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Neos Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Neos Therapeutics investors own include Verastem (VSTM), SCYNEXIS (SCYX), TherapeuticsMD (TXMD), TG Therapeutics (TGTX), AcelRx Pharmaceuticals (ACRX), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL), Progenics Pharmaceuticals (PGNX), T2 Biosystems (TTOO) and Agile Therapeutics (AGRX).
When did Neos Therapeutics IPO?: Neos Therapeutics (NEOS) raised $60 million in an IPO on Thursday, July 23rd 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

This page (NASDAQ:NEOS) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Neos Therapeutics (NEOS) Stock Price, News & Analysis

About Neos Therapeutics Stock (NASDAQ:NEOS)

NEOS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

NEOS Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info